Barbara Elashoff.

For gene-expression testing, a score below 34 was found in the majority of cases to recognize patients who have been at low risk for rejection and in whom a biopsy had not been needed. Although the use of an increased threshold may further minimize the number of biopsies needed, the results of our trial suggest that a score below 34 represents a prudent threshold to make use of in clinical practice in the case of patients for whom the interval after transplantation is more than 6 months. There have been fewer treated episodes of rejection in the gene-profiling group than in the biopsy group, which difference was due mainly to fewer asymptomatic episodes of rejection observed in the gene-profiling group than in the biopsy group .

This content was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family members Foundation. Kaiser Health News, an editorially independent news service, is a scheduled plan of the Kaiser Family members Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Accuray, University of Heidelberg enter multi-year master study and collaboration agreement Accuray Integrated , the premier radiation oncology company, announced today the signing of a multi-year master research and collaboration agreement with the University of Heidelberg, a luminary research organization situated in Heidelberg, Germany that contributes to the city’s best international placement in therapy, science and research.This content was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family members Foundation. Kaiser Health News, an editorially independent news service, is a scheduled plan of the Kaiser Family members Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Accuray, University of Heidelberg enter multi-year master study and collaboration agreement Accuray Integrated , the premier radiation oncology company, announced today the signing of a multi-year master research and collaboration agreement with the University of Heidelberg, a luminary research organization situated in Heidelberg, Germany that contributes to the city’s best international placement in therapy, science and research.